Md Saiful Islam Khan/iStock via Getty Images
- Gossamer Bio (GOSS) has submitted an NDA to the US FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH).
- The application is supported by data from the phase 3 PROSERA study, evidence from the phase 2 TORREY study, and supportive analyses.